BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 1, 2007
View Archived Issues
Recent RTI patent discloses novel therapeutic agents for irritable bowel syndrome
Read More
New agents for endocrine-related disorders imparted in recent patent literature
Read More
Recent patents disclose novel agents for obesity and disorders of lipid and bone metabolism
Read More
Studies reveal efficacy of fluticasone furoate nasal spray in allergic rhinitis
Read More
New trial evaluates topiramate and almotriptan for the treatment of medication overuse headache
Read More
Atorvastatin to be tested in new clinical trial for systemic lupus erythematosus
Read More
Vandetanib begins new phase III trial with pemetrexed for NSCLC
Read More
Javelin signs commercial supply agreement for Dyloject
Read More
Samaritan to market Elaprase in Greece and Cyprus
Read More
Second phase I trial of NGX-426 for chronic pain
Read More
DEBIO-9902 SR implant studied in phase II trial for Alzheimer's
Read More
BiPar Series B financing to support PARP inhibitor development
Read More
Roche and Kosan advance second-generation epothilone into phase II
Read More
Inex eyes close of Tekmira spin-out
Read More
Oral salmon calcitonin begins phase III study in osteoporosis
Read More
Vaccinex and Teva collaborate on VX-15
Read More
Paclitaxel poliglumex active, well tolerated in androgen-independent prostate cancer
Read More
MAP's Unit Dose Budesonide meets endpoints in phase II pediatric asthma trial
Read More
DMXAA increases efficacy of docetaxel in hormone-refractory prostate cancer
Read More
Par returns difimicin marketing rights to Optimer
Read More
Abiraterone active in androgen-independent, castration refractory prostate cancers
Read More
Maturation inhibitor PA-040 begins phase I study
Read More
CYT-500 enters clinic for hormone-refractory prostate cancer
Read More
Identification of ecallantide, an engineered, potent and selective inhibitor of plasma kallikrein
Read More
Humira approved for Crohn's disease
Read More
Cellular and molecular targets in tumor microenvironment considered for chemoprevention
Read More